BR112012000036A2 - hyr1 como um alvo para imunização ativa e passiva contra candida - Google Patents

hyr1 como um alvo para imunização ativa e passiva contra candida

Info

Publication number
BR112012000036A2
BR112012000036A2 BR112012000036A BR112012000036A BR112012000036A2 BR 112012000036 A2 BR112012000036 A2 BR 112012000036A2 BR 112012000036 A BR112012000036 A BR 112012000036A BR 112012000036 A BR112012000036 A BR 112012000036A BR 112012000036 A2 BR112012000036 A2 BR 112012000036A2
Authority
BR
Brazil
Prior art keywords
hyr1
candida
immunization
passive
target
Prior art date
Application number
BR112012000036A
Other languages
English (en)
Portuguese (pt)
Inventor
Fu Yue
Luo Guanpingsheng
Ibrahim Ashraf
J. Spellberg Brad
E. Edwards John Jr.
Original Assignee
Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center filed Critical Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center
Publication of BR112012000036A2 publication Critical patent/BR112012000036A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/37—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from fungi
    • C07K14/39—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from fungi from yeasts
    • C07K14/40—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from fungi from yeasts from Candida
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0002—Fungal antigens, e.g. Trichophyton, Aspergillus, Candida
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Passenger Equipment (AREA)
BR112012000036A 2009-07-03 2010-07-02 hyr1 como um alvo para imunização ativa e passiva contra candida BR112012000036A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US22300509P 2009-07-03 2009-07-03
PCT/US2010/040949 WO2011003085A1 (en) 2009-07-03 2010-07-02 Hyr1 as a target for active and passive immunization against candida

Publications (1)

Publication Number Publication Date
BR112012000036A2 true BR112012000036A2 (pt) 2018-04-03

Family

ID=43411487

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112012000036A BR112012000036A2 (pt) 2009-07-03 2010-07-02 hyr1 como um alvo para imunização ativa e passiva contra candida

Country Status (15)

Country Link
US (2) US8709446B2 (https=)
EP (1) EP2448959B1 (https=)
JP (2) JP5690822B2 (https=)
KR (1) KR20120085234A (https=)
CN (1) CN102574895B (https=)
AU (2) AU2010266114B2 (https=)
BR (1) BR112012000036A2 (https=)
CA (1) CA2766805A1 (https=)
ES (1) ES2606555T3 (https=)
IL (1) IL217261A0 (https=)
MX (1) MX2012000018A (https=)
NZ (1) NZ597442A (https=)
RU (2) RU2559537C2 (https=)
SG (1) SG177456A1 (https=)
WO (1) WO2011003085A1 (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070077256A1 (en) 1999-11-19 2007-04-05 Los Angeles Biomedical Research Institute Pharmaceutical compositions and methods to vaccinate against disseminated candidiasis and other infectious agents
WO2011003085A1 (en) 2009-07-03 2011-01-06 Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center Hyr1 as a target for active and passive immunization against candida
GEP201706766B (en) 2011-07-22 2017-10-25 Los Angeles Biomedical Res Center Methods and compositions for vaccinating against staphylococcus aureus
BR112014005773A2 (pt) * 2011-09-14 2019-09-24 Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center composições derivadas de hyr1 e métodos of tratamento usando as mesmas
WO2014144024A1 (en) * 2013-03-15 2014-09-18 Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center Hyr1 compositions and methods for treating fungal and bacterial pathogens
US10130691B2 (en) 2013-03-15 2018-11-20 Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center Compositions and methods for treating fungal and bacterial pathogens
GB201306588D0 (en) 2013-04-11 2013-05-29 King S College London Peptides and Binding Partners Therefor
EP3426287A4 (en) 2016-03-09 2020-03-11 Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center Methods and kits for use in preventing and treating vulvovaginal candidiasis
CN113508176A (zh) 2019-02-28 2021-10-15 米尼翁大学 用于控制白色念珠菌感染的反义寡聚物
CN110229221B (zh) * 2019-06-27 2022-04-12 上海交通大学医学院附属仁济医院 一种用于检测侵袭性白色念珠菌病的抗原及其用途
US20220354935A1 (en) * 2021-04-21 2022-11-10 Lundquist Institute For Biomedical Innovation At Harbor-Ucla Medical Center Vaccination against fungal epitopes to prevent inflammatory bowel diseases
WO2025248488A1 (en) * 2024-05-29 2025-12-04 Lundquist Institute For Biomedical Innovation At Harbor-Ucla Medical Center Compositions and methods for preventing and treating healthcare-associated candida auris infections with dual antigen vaccine

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995031998A1 (en) 1994-05-23 1995-11-30 The Research & Development Institute, Inc. Candida albicans adhesin as a vaccine
US6747137B1 (en) * 1998-02-13 2004-06-08 Genome Therapeutics Corporation Nucleic acid sequences relating to Candida albicans for diagnostics and therapeutics
US20070077256A1 (en) * 1999-11-19 2007-04-05 Los Angeles Biomedical Research Institute Pharmaceutical compositions and methods to vaccinate against disseminated candidiasis and other infectious agents
US20060083750A1 (en) * 1999-11-19 2006-04-20 Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center Pharmaceutical compositions and methods to vaccinate against disseminated candidiasis
US6734344B2 (en) * 1999-12-10 2004-05-11 Her Majesty The Queen In Right Of Canada, As Represented By The Minister Of Agriculture And Agrifood Coniothyrium minitans β-(1,3) exoglucanase gene cbeg 1
US7241613B1 (en) * 2002-06-05 2007-07-10 Oscient Pharmaceuticals Corporation Identification of Candida cell surface proteins and their uses
RU2316595C1 (ru) * 2006-06-16 2008-02-10 Институт биоорганической химии им. академиков М.М. Шемякина и Ю.А. Овчинникова Российской академии наук Способ получения антимикробного пептида ареницина
WO2011003085A1 (en) 2009-07-03 2011-01-06 Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center Hyr1 as a target for active and passive immunization against candida

Also Published As

Publication number Publication date
KR20120085234A (ko) 2012-07-31
EP2448959B1 (en) 2016-09-07
AU2016244238A1 (en) 2016-10-27
EP2448959A4 (en) 2013-01-02
AU2010266114B2 (en) 2016-07-14
RU2012103502A (ru) 2013-08-10
SG177456A1 (en) 2012-02-28
RU2015122387A (ru) 2015-10-27
US8709446B2 (en) 2014-04-29
MX2012000018A (es) 2012-03-29
NZ597442A (en) 2014-01-31
CN102574895B (zh) 2014-06-11
WO2011003085A1 (en) 2011-01-06
IL217261A0 (en) 2012-02-29
JP2015120722A (ja) 2015-07-02
ES2606555T3 (es) 2017-03-24
RU2015122387A3 (https=) 2019-01-28
RU2559537C2 (ru) 2015-08-10
WO2011003085A9 (en) 2011-07-28
CA2766805A1 (en) 2011-01-06
CN102574895A (zh) 2012-07-11
JP5690822B2 (ja) 2015-03-25
JP2012532114A (ja) 2012-12-13
US20140335114A1 (en) 2014-11-13
EP2448959A1 (en) 2012-05-09
AU2010266114A1 (en) 2012-02-02
US20120237534A1 (en) 2012-09-20

Similar Documents

Publication Publication Date Title
BR112012000036A2 (pt) hyr1 como um alvo para imunização ativa e passiva contra candida
EP2637901A4 (en) ACTIVE UPHOLSTERY
EP2346734A4 (en) ACTIVE WINGLET
IL215871B (en) Method for improving the dissolutionprofile of a biologically active material
BRPI1015238A2 (pt) diamidas de azetidilina como inibidores de monoaciglicerol lipase
FR2971145B1 (fr) Implant de corporectomie
BR112014029904A2 (pt) implante lateralmente defletível , conjunto e método para a implantação num corpo
BRPI1009454A2 (pt) vacinas contra o câncer direcionadas a células apresentadoras de antígenos
FR2947716B1 (fr) Implant prothetique ameliore
EP2606370A4 (en) ACTIVE POSITIONING SYSTEM
HUE066764T2 (hu) Szívbillentyû implantátum
DK3491915T5 (da) Fremgangsmåde til at inducere en målrettet translokation i en plante
BR112014006912A2 (pt) método para intensificar o crescimento de plantas de milho
EP2539015A4 (en) RETINA GRAFT
SI2507506T1 (sl) Z morjem gnano energetsko postrojenje
EP2317984A4 (en) ARTICLE FOR THE RELEASE OF AN ACTIVE SUBSTANCE
EP2413845A4 (en) Stent
BR112013011856A2 (pt) sistema de implante dental e processo para a fabricação de um sistema de implante dental
BR112013012309A2 (pt) composto, composição, métodos de tratamento e usos de um composto
BRPI1008744A2 (pt) hidrotratamento de caboidratos
EP2600446A4 (en) NEGATIVE ACTIVE MATERIAL
UY33155A (es) Indolil-piperidinil bencilaminas como inhibidores de beta-triptasa
FI20095062A0 (fi) Kasvien viljelymenetelmä
BR112013015979A2 (pt) tampão de fratura modular e método para a construção do mesmo
GB2478954B (en) Active target

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 9A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO ARQUIVAMENTO PUBLICADO NA RPI 2521 DE 30/04/2019.